Dexmedetomidine attenuates persistent postsurgical pain by upregulating K⁺–Cl⁻ cotransporter-2 in the spinal dorsal horn in rats

This article was published in the following Dove Press journal:
Journal of Pain Research

Shuhong Dai¹
Yu Qi¹
Jie Fu¹
Na Li¹
Xu Zhang¹
Juan Zhang²
Wei Zhang²
Haijun Xu¹
Hai Zhou¹
Zhengliang Ma²

¹Department of Anesthesiology, XuZhou Central Hospital, Xuzhou, China; ²The Affiliated Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China

Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). In addition, KCC2-induced shift in neuronal Cl⁻ homeostasis is crucial for postsynaptic inhibition mediated by GABAA receptors. Accumulating evidence shows that nerve injury, peripheral inflammation and stress activate the spinal BDNF/TrkB signal, which results in the downregulation of KCC2 transport and expression, eventually leads to GABAergic disinhibition and hyperalgesia. The aim of this experiment was to explore the interaction between DEX and KCC2 at a molecular level in rats in the persistent postsurgical pain (PPSP).

Methods: PPSP in rats was evoked by the skin/muscle incision and retraction (SMIR). Mechanical hypersensitivity was assessed with the Dynamic Plantar Aesthesiometer. Western blot and immunofluorescence assay were used to assess the expressions of related proteins.

Results: In the first part of our experiment, the results revealed that the BDNF/TrkB-KCC2 signal plays a critical role in the development of SMIR-evoked PPSP; the second part showed that intraperitoneal administrations of 40 µg/kg DEX at 15 min presurgery and 1 to 3 days post-surgery significantly attenuated SMIR-evoked PPSP. Simultaneously, SMIR-induced KCC2 downregulation was partly reversed, which coincided with the inhibition of the BDNF/TrkB signal in the spinal dorsal horn. Moreover, intrathecal administrations of KCC2 inhibitor VU0240551 significantly reduced the analgesic effect of DEX on SMIR-evoked PPSP.

Conclusion: The results of our study indicated that DEX attenuated PPSP by restoring KCC2 function through reducing BDNF/TrkB signal in the spinal dorsal horn in rats, which provides a new insight into the treatment of chronic pain in clinical postsurgical pain management.

Keywords: skin/muscle incision and retraction, persistent postsurgical pain, dexmedetomidine, KCC2, BDNF/TrkB signal

Introduction
Persistent postsurgical pain (PPSP) is a serious issue in clinical pain management because it slows surgical recovery, prolongs hospitalization, lowers the patient’s quality of life, and increases economic consequences.¹ Moreover, PPSP has a high prevalence,² particularly in certain surgeries that require essential prolonged tissue retraction, such as thoracotomy and inguinal hernia repair.³,⁴ However, the process of PPSP is still poorly understood.

In recent years, there has been sustained and enhanced interest among researchers and clinicians in exploring the role of GABAergic disinhibition in a series of pathological states, such as hyperalgesia.⁵–⁷ One of the most important areas in this
selective agonist of \( \alpha_2 \)-adrenergic receptors with sedative properties, has been promoted for its palpable analgesic effects in the microglia of the spinal dorsal horn.\(^{22}\) Even though the mechanism of action of DEX is not fully understood, it is known that DEX modulates pain through the downregulation of P2X receptors in the sciatic nerve spared nerve injury (SNI)-induced neuropathic pain model.\(^{23}\) In a recent study, intraperitoneal (IP) injections of 40 \( \mu \)g/kg DEX for 14 consecutive days clearly reversed the neuropathic pain state in rats.\(^{24}\)

Animal pain behaviors were assessed at postoperative days (PODs) 1, 3, 7, 12, 22, and 32 after SMIR surgery (\( n = 8 \)/group). At POD 12, rats were sacrificed to remove the L4-6 spinal cord for Western blotting and immunofluorescence assay (\( n = 5 \)/group).

**Materials and methods**

**Animals**

The experiments were performed on male adult Sprague Dawley rats (6–8 weeks; 180–220 g). They were housed in the animal facility under a 12-h light–dark cycle with food and water freely available. In addition, the room temperature and humidity were well controlled. All procedures were approved by the Animal Care Committee of Nanjing Medical University (IACUC protocol number: NJMU08-092) in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No 80-23) revised 1996; in addition, efforts were made to minimize the number of animals used for the experiments and their suffering.

**Experimental design**

Part 1: we explored the role of the BDNF/TrkB-KCC2 signal in SMIR-evoked PPSP in rats and the interaction with KCC2 at a molecular level in the spinal dorsal horn

In section 1, 129 rats were equally randomized into two groups: normal, sham, and SMIR. Animal pain behavior was assessed at postoperative days (PODs) 1, 3, 7, 12, 22, and 32 after SMIR (\( n = 8 \)/group), randomly chosen from each group and fixed for the evaluation. At each time point after the behavioral assessment, rats were randomly sacrificed to isolate the L4-6 spinal cords for Western blotting (\( n = 5 \)/group/time point), while five rats from each group were sacrificed to remove the L4-6 spinal cords for immunofluorescence assay at POD 12.

In section 2, 72 rats were equally randomized into four groups: sham + saline, sham + TrkB/Fc, SMIR + saline, and SMIR + TrkB/Fc. The sham + TrkB/Fc and SMIR + TrkB/Fc groups were intrathecally injected with 5 \( \mu \)g TrkB/Fc (Sigma-Aldrich Co., St Louis, MO, USA) (dissolved in 10 \( \mu \)L saline), while the sham + saline and SMIR + saline groups were intrathecally injected with the same volume of saline. Animal pain behaviors were assessed at PODs 1, 3, 7, 12, 22, and 32 after SMIR surgery (\( n = 8 \)/group). At POD 12, rats were sacrificed to remove the L4-6 spinal cord for Western blotting and immunofluorescence assay (\( n = 5 \)/group).

**Paw mechanical withdrawal threshold (PMWT) test**

The PMWT in the ipsilateral paw was assessed using the Dynamic Plantar Aesthesiometer (Ugo Basile S.R.L., Gemino VA, Italy).\(^{25}\) Rats were placed in the boxes for 30 min
before the test to adapt to the environment. The filament containing a universal tip exerted an upward force on the plantar surface of the hindpaw (maximum 50 g), and the results were automatically showed by the intensity of hypernociception (in grams) following hindpaw withdrawal. The average of five measurements was considered as the PMWT, and the presurgery PMWT was considered to be the baseline value.

**SMIR surgery**

The SMIR model was built according to the technique described by Flatters. The rats were anesthetized through IP administration of phenobarbital (60 mg/kg). First, at a position ~4 mm medial to the saphenous vein, a 1.5–2 cm incision was made in the skin of the medial thigh, followed by a 7–10 mm incision in the superficial (gracilis) muscle layer of the thigh. The superficial muscle was then parted further with blunt scissors to allow a microdissecting retractor to be inserted. The skin and superficial muscle of the thigh were retracted to reveal 2 cm of the fascia of the underlying adductor for 1 h, after which the incision was closed with 4.0 Vicryl sutures. Rats in the groups receiving sham surgery underwent the same procedure without skin/muscle retraction.

**Intrathecal method**

The intrathecal injections were made by percutaneous intrathecal puncture technique with a microsyringe. The lumbar regions of rats were shaved followed by the preparation of Betadine Solution and placed on a plexiglas tube to make the intervertebral spaces widened. Then, rats were injected at the lumbar interspace (L4–6) using a Hamilton microsyringe filled with necessary drugs. The correct subarachnoid position appeared at the falling sense and was verified by the paw-flick or tail test.

The technique not only has a high success rate but also has safe and reliable without spinal cord damage. Moreover, with the advantage of small trauma, rapid recovery after surgery, reduced leakage of cerebrospinal fluid, and reusable, this technique could avoid the intrathecal catheter-induced inflammatory response and the adverse effects on drug function and pain response.

**Western blotting analysis**

The L4–6 spinal dorsal horn was rapidly isolated and stored at −80°C for subsequent procedures. The frozen ipsilateral dorsal horn was prepared after tissue lysis and centrifugation for SDS-polyacrylamide gel electrophoresis. The protein with the SDS sample buffer was either mixed with β-mercaptoethanol or not, separated under reducing conditions on a 5% SDS-polyacrylamide gel and finally transferred to a nitrocellulose membrane. The membrane was incubated with mouse anti-KCC2 (1:300; Sigma-Aldrich Co.), anti-BDNF (1:250; Sigma-Aldrich Co.), and anti-TrkB (1:500; Abcam, Cambridge, MA, USA). β-Actin (1:1000; Sigma-Aldrich Co.) was used as a standard. After overnight agitation at 4°C, the sample was then incubated with HRP-conjugated goat antimouse antibody (1:1500) for 1 h at room temperature. The bands were acquired by enhanced chemiluminescence (ECL) (GE Healthcare Biosciences, Piscataway, NJ, USA) and analyzed using ImageJ (National Institutes of Health, Bethesda, MA, USA).

**Immunofluorescence assay**

After being deeply anesthetized, rats were fixed with 4% paraformaldehyde and perfused with saline. The L4-6 spinal cord was harvested, postfixed overnight, and cryopreserved in 30% sucrose. Sections of a 20 µm thickness were cut with cryostat (Leica Microsystems, Wetzlar, Germany) at −20°C. Slices were blocked with 0.2% Triton X-100 and incubated overnight at 4°C with mouse anti-KCC2 (1:300; Sigma-Aldrich Co.). After being washed three times, sections were incubated in Alexa594-conjugated goat antimouse antibody (1:800; Life Sciences, Pittsburgh, PA, USA) for 2 h and washed with PBS before mounting. ImageJ software was used to analyze the average optical density of KCC2 expression in the spinal dorsal horn.

**Data analysis and statistics**

SPSS, Version 18 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The results were expressed as the mean ± standard error of the mean (SEM). Two-way analysis of variance (ANOVA) followed by an LSD post hoc comparison was used to compare the nociceptive thresholds to mechanical stimuli with group and time. Western blot and immunofluorescence results were compared by one-way ANOVA and two-way ANOVA (for multiple groups comparison) when necessary. The figures were all created with GraphPad Prism software, Version 4.0. P<0.05 was considered statistically significant.

**Results**

**Decrease in PMWT following SMIR**

As shown in Figure 1A, no statistically significant difference in the PMWT was observed between the normal and sham groups (P>0.05). In the SMIR group, the PMWT in the ipsilateral paw to surgery was significantly and persistently lowered at PODs 3–22 (P=0.004, P=0.005, P=0.003, P=0.000, F=22.978). A comparison of the PMWT in the SMIR group with that of the normal and sham groups
revealed significant differences at PODs 3–22 ($P=0.000$, $F=26.746$, $P<0.05$).

**Time course of protein expressions of BDNF and TrkB in the ipsilateral spinal dorsal horn after SMIR**

As shown in Figure 1B–D, the results of Western blot indicated that compared with the baseline and the normal and sham groups, SMIR rats appeared to be upregulated in BDNF and TrkB proteins after surgery in the ipsilateral dorsal horn of the L4–6 spinal cord ($P=0.001$, $F=92.903$), while no differences were found between the normal and sham groups ($P>0.05$).

**Downregulation of KCC2 expression in the ipsilateral spinal dorsal horn after SMIR**

The expression level of KCC2 in the ipsilateral L4–6 spinal dorsal horn of the SMIR rats clearly decreased with the same time course as the BDNF/TrkB signal ($P=0.002$, $F=59.366$, Figure 2A and B). To further explore whether SMIR affects KCC2 oligomerization, which was critical for the transport ability of KCC2, we assessed KCC2 expression with a non-sulfhydryl-reducing sample buffer as previously described.28 The results showed that the KCC2 oligomer ($P=0.000$, $F=277.006$) and monomer ($P=0.000$, $F=645.164$) and the oligomer/monomer ratio were significantly downregulated after SMIR in the ipsilateral spinal dorsal horn, accompanied by pain behaviors (Figure 2C–F). Immunofluorescence assay confirmed the decrease of KCC2 expression in the spinal dorsal horn after SMIR (Figure 3, $P<0.05$)

**BDNF-sequester TrkB/Fc significantly reversed SMIR-induced changes in rats**

To further verify the interaction between the BDNF/TrkB signal and KCC2 in the spinal dorsal horn of PPSP rats, we
intrathecally administered 5 µg TrkB/Fc at 15 min presurgery and at PODs 1–3. No differences were detected between the sham + saline group and the sham + TrkB/Fc group (P>0.05). The PMWT values of the SMIR + saline group decreased significantly after the SMIR surgery (P=0.000, F=19.732, Figure 4A). Compared with the SMIR + saline group, the PMWT in the SMIR + TrkB/Fc group significantly increased but was still lower than in the groups that received the sham procedure (P=0.045, F=3.053, Figure 4A).

The Western blot analysis (P=0.011, F=93.353) and immunofluorescence assay revealed that KCC2 expression in the ipsilateral spinal dorsal horn was significantly downregulated in the SMIR + saline and SMIR + TrkB/Fc groups compared to the sham + saline and sham + TrkB/Fc groups; but compared with the SMIR + saline group, KCC2 expression was clearly upregulated (Figure 4B and C, P<0.05).

**IP injections of DEX attenuated the SMIR-evoked PPSP**

In our study, DEX was administered 15 min presurgery and at PODs 1–3, which was consistent with clinical multimodal analgesia. After IP injections of 40 µg/kg DEX, rats presented mild drowsiness and reduced locomotor activity but could be easily awoken without significant barrier to activities. Rats without DEX administration did not show any loss of consciousness or movement disorders. A short time later, no obvious differences were observed in all rats with normal activity and righting reflex.

No differences were detected between the sham + saline and sham + DEX groups (P>0.05). A comparison of the SMIR + saline group’s PMWT values with those of the sham + saline or sham + DEX groups revealed significant differences after the surgery. Compared with the SMIR + saline group, the PMWT in the SMIR + DEX group significantly increased but was still lower than in the groups that received the sham procedure (P=0.001, F=12.989, Figure 5).

**Effects of DEX on the protein expressions of BDNF and TrkB in the ipsilateral spinal dorsal horn in SMIR rats**

Western blot analysis revealed that IP administrations of DEX significantly inhibited SMIR-induced upregulation of BDNF and TrkB in the dorsal horn of the ipsilateral L4-6 spinal cord in the SMIR + DEX group versus the SMIR + saline group rats, but the protein expressions were still higher than in the sham + saline and sham + DEX groups (P <0.001,
No differences were observed between the sham + saline and sham + DEX groups (Figure 6A–C).

**The effect of DEX on KCC2 expression in the ipsilateral spinal dorsal horn in SMIR rats**

KCC2 expression in the dorsal horn of the ipsilateral L4-6 spinal cord in the SMIR + DEX group clearly increased compared to that in the SMIR + saline group ($P=0.001$, $F=708.051$; Figure 6A and D). Furthermore, compared with the SMIR + saline group, the KCC2 monomer, oligomer, and oligomer/monomer ratio were upregulated in the SMIR + DEX group but were still lower than in the sham + saline and sham + DEX groups (Figure 7A–D, $P<0.05$). Additionally, we studied the effect of DEX on KCC2 expression in the spinal dorsal horn by immunofluorescence assay. No significant difference between the sham + saline and sham + DEX groups was detected in KCC2 expression in the ipsilateral spinal dorsal horn ($P>0.05$). Marked upregulation of KCC2 was found in the SMIR + DEX group compared to SMIR + saline group but was still lower than in the sham + saline and sham + DEX groups (Figure 7E and F, $P<0.05$).

**KCC2 inhibitor VU0240551 reduced the analgesic effect of DEX on SMIR-evoked PPSP and downregulated KCC2 in the ipsilateral spinal dorsal horn**

To further verify our hypotheses, we intrathecally administered 0.27 µg KCC2 inhibitor VU0240551 15 min presurgery and at PODs 1–3 in DEX-treated rats. The results showed that compared with the SMIR + DEX + DMSO group, the PMWT
of the SMIR + DEX + VU0240551 group was significantly lower after SMIR surgery ($P=0.006, F=11.760$, Figure 8A). The Western blot analysis and immunofluorescence assay revealed that KCC2 expression in the ipsilateral spinal dorsal horn in the SMIR + DEX + VU0240551 group clearly decreased compared with the SMIR + DEX + DMSO group ($P<0.05$, Figure 8B–E).

**Discussion**

Although a considerable number of drugs are used for clinical analgesia, PPSP still has a high prevalence, particularly in certain surgeries that require essential prolonged tissue retraction, such as thoracotomy and inguinal hernia repair, so novel mechanism-based treatments are severely lacking and are undoubtedly required for postsurgical pain management. To better approach this problem, in 2008, Flatters proposed an SMIR-evoked PPSP model to mimic clinical surgeries that require prolonged tissue retraction without damaging the saphenous nerve. In the present study, we observed that the PMWT significantly decreased and remained at a low level throughout the experiment in the ipsilateral hindpaw of rats that received SMIR surgery (Figure 1). It is notable that, unlike the model in which intercostal nerve damage was closely associated with the degree and incidence of postoperative pain described by Buvanendran et al., there were no obviously damaged main nerves in the SMIR model.

One of the main findings of our experiment was the role of KCC2 in the spinal dorsal horn in SMIR-evoked PPSP. The data to date suggest that in pain-signaling pathways, GABAergic inhibition loss plays a critical role in central sensitization, which is indispensable for the acute–chronic pain conversion. One main reason for the transition is the impaired intracellular chloride homeostasis due to the decreased activity and expression of KCC2, a postsynaptically restricted $\text{Cl}^-/\text{K}^+$ cotransporter that is crucial for postsynaptic inhibition mediated by GABA$_A$ receptors. Previous studies
have shown that downregulation of KCC2 contributes to the early behavioral signs of hyperalgesia induced by loose ligation of the sciatic nerve, morphine-induced hyperalgesia, and persistent inflammation pain resulting from the activation of the descending pain-facilitating pathway, which may be critical in the process of central sensitization during the acute–chronic pain conversion. Pharmacological inhibition of KCC2 by its inhibitor, VU0240551, leads to thermal hypersensitivity in normal rats, while rescuing the plasma membrane expression of KCC2 using CLP257, an analog of CL058 with better chemical stability and overall properties, reduced $[\text{Cl}^-]$ at a maximum of $\sim 40\%$, arouse KCC2 transport activity by $61\% (P<0.01)$, and substantially increased the $\text{Cl}^-$ transport, which could obviously alleviate the hyperalgesia of neuropathic pain in rats, further indicating that KCC2 is necessary and sufficient for nociception modulation. However, the role of KCC2 in SMIR-evoked PPSP is still to be elucidated. In our present experiment, we found a significant and prolonged reduction of KCC2 expression in the spinal dorsal horn following SMIR and the time course of variations was in agreement with the decline of the PMWT. More specifically, functional KCC2 exists mostly in the form of oligomers on the membrane surface of mature neurons and altered KCC2 oligomerization and clusters would lead to a loss of KCC2 transport activity, which is closely associated with the modulation of nociception. In the SMIR-evoked PPSP model, we also observed significant decrease in KCC2 oligomerization, indicating that KCC2 downregulation was at least partly involved in the process of central sensitization during the acute–chronic pain conversion in SMIR-evoked PPSP, which may provide a novel guidance for the treatment of postoperative chronic pain.

Another important finding was the modulation of the BDNF/TrkB signal on KCC2 in the spinal dorsal horn of SMIR-evoked PPSP rats. We observed a simultaneous time course of variations in KCC2 and the BDNF/TrkB signal in the spinal dorsal horn following SMIR. It has been well documented that BDNF is an important regulator for pain transmission in the spinal dorsal horn, which mainly functions through its high-affinity TrkB, specifically the BDNF/TrkB signal. The signal was originally found to downregulate KCC2 in the hippocampal culture, but later, more direct supporting evidence verified that downregulation of KCC2 induced by the activation of the BDNF/TrkB signal is responsible for the disinhibition of GABAergic neurons under sensitized pain conditions, and blocking the signal between

Figure 5 IP administration of 40 μg/kg DEX 15 min presurgery and at PODs 1–3 significantly attenuated the SMIR-evoked PPSP in rats.

Notes: Compared with the SMIR + saline group, the PMWT of the SMIR + DEX rats significantly increased but was still lower than in the sham + saline and sham + DEX groups ($n=8$). *$P<0.05$ vs sham + saline group, $\#P<0.05$ vs sham + DEX group, and $+P<0.05$ vs SMIR + saline group.

Abbreviations: DEX, dexmedetomidine; IP, intraperitoneal; PMWT, paw mechanical withdrawal threshold; PODs, postoperative days; PPSP, persistent postsurgical pain; SMIR, skin/muscle incision and retraction.
Dexmedetomidine attenuates PPSP

BDNF and TrkB reversed the E (anion) shift and hyperalgesia/allodynia.7,11,12,35 In our experiment, blocking the BDNF/TrkB signal by intrathecal administrations of BDNF-sequester TrkB/Fc significantly attenuated the SMIR-evoked PPSP and upregulated KCC2 expression in the spinal dorsal horn, to some extent indicating that the BDNF/TrkB-KCC2 signal plays a key role in the development of SMIR-evoked PPSP.

Previous studies have reported that the main site in which α2-adrenoceptors’ agonists function is the spinal cord,39 where the activation of α2-adrenoceptors directly blocks the nociceptive neurotransmission.40,41 Functional α2-adrenoceptors’ alterations and actions of BDNF on cholinergic terminals after peripheral nerve injury play a vital role in the function of analgesics commonly used to treat neuropathic pain.42 Recently, DEX, a highly selective agonist of α2-adrenergic receptors, has attracted researchers’ interest because of its good analgesic properties, which are comparable to opioids without the side effects of the latter, such as dependence and tolerance.19,20,22,23 To date, the mechanisms of analgesic effects in neuropathic pain reportedly involve in the downregulation of P2×4Rs, p-p38, and BDNF in the microglia of the spinal dorsal horn;22 the activation of α2-adrenoceptor augmented by increased Ach in the lumbar spinal cord;20 and the augmentation of inhibitory synaptic transmission in the superficial dorsal horn by activating the descending noradrenergic control.16 However, the interaction between DEX and KCC2 at a molecular level in the development of PPSP is still to be explored. IP administration was selected in our study because DEX is highly lipid soluble; in addition, after systemic administration, it could readily

![Figure 6](image url) Effect of DEX IP administration 15 min presurgery and at PODs 1–3 on the expressions of BDNF, TrkB, and KCC2 in the spinal dorsal horn.

**Notes:** Western blot displayed that DEX treatment inhibited BDNF/TrkB signal expression (A–C) and upregulated KCC2 expression (A and D) in the spinal dorsal horn of the SMIR + DEX group (n=5/time point). *P<0.05 vs sham + saline, †P<0.05 vs sham + DEX, and ‡P<0.05 vs SMIR + saline.

**Abbreviations:** BDNF, brain-derived neurotrophic factor; DEX, dexmedetomidine; IP, intraperitoneal; PODs, postoperative days; SMIR, skin/muscle incision and retraction.
cross the blood–brain barrier. Administrations 40 µg/kg DEX at 15 min presurgery and at PODs 1–3 were carried out in accordance with recommendations for clinical multimodal analgesia and previous reports.21,22 In our experiment, it was observed that IP administrations of DEX significantly attenuated the postoperative persistent pain and the BDNF/TrkB-KCC2 signal was partly reversed in the spinal dorsal horn. Moreover, KCC2 inhibitor VU0240551 administrations significantly reduced the analgesic effect of DEX on SMIR-evoked PPSP. At the same time, KCC2 expression was also clearly lower than in the DEX-treated group, which further verifies the role of KCC2 in the analgesic effect of DEX on SMIR-evoked PPSP.

**Conclusion**

In the present study, we explored the role of BDNF/TrkB-KCC2 in the analgesic effect of DEX on SMIR-evoked PPSP. The results suggest that DEX significantly alleviates the development of SMIR-evoked PPSP, while the BDNF/TrkB-KCC2 signal in the spinal dorsal horn might account for the analgesic mechanisms.

**Acknowledgment**

This study was supported by the National Natural Science Foundation of China (Nos 81171048, 81171047, and 81471129).

**Author contributions**

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Macrae W. Chronic post-surgical pain: 10 years on. *Br J Anaesth.* 2008;101(1):77–86.
Figure 8. KCC2 inhibitor VU0240551 intrathecally administered at 15 min presurgery and at PODs 1–3 reduced the effect of DEX on SMIR rats.

Notes: (A) The influence of VU0240551 on the analgesic effect of DEX in SMIR-induced PPSP rats. (B and C) KCC2 expression in the SMIR + DEX + VU0240551 group was significantly inhibited compared with the SMIR + DEX + DMSO group. (D and E) KCC2 expression in the ipsilateral spinal dorsal horn (a) and KCC2 expression in the superficial dorsal horn layers (b). Magnification: a =50× and b =400×. Scale bar: 20 mm. *P<0.05 vs SMIR + DEX + DMSO group.

Abbreviations: DEX, dexmedetomidine; PODs, postoperative days; SMIR, skin/muscle incision and retraction.
12. Miletic G, Miletic V. Loss of glial cells in the sciatic nerve is associated with TRKβ receptor-dependent decreases in KCC2 protein levels in the ipsilateral spinal dorsal horn. Pain. 2008;137(3):532–539.

13. Dufo F, Li X, Bantel C, Pancaro C, Vincler M, Eisenach JC. Peripheral nerve injury alters the ε2 adrenoceptor subtype activated by clonidine for analgesia. Anesthesiology. 2002;97(3):636–641.

14. Paqueron X, Conklin D, Eisenach JC. Plasticity in action of intrathecal clonidine to mechanical but not thermal nociception after peripheral nerve injury. Anesthesiology. 2003;99(1):199–204.

15. Hajhashemi V, Banafshe HR, Minaiyan M, Mesdaghinia A, Abad A. Antinoceptive effects of venlafaxine in a rat model of peripheral neuropathy: role of alpha2-adrenergic receptors. Eur J Pharmacol. 2014;738:230–236.

16. Funai Y, Pickering AE, Uta D, et al. Systemic dexmedetomidine augments inhibitory synaptic transmission in the superficial dorsal horn through activation of descending noradrenergic control: an in vivo patch-clamp analysis of analgesic mechanisms. Pain. 2014;155(3):617–628.

17. Zhang H, Yan X, Wang D-G, et al. Dexmedetomidine relieves formalin- and saline-induced pain in rats through both ε2 adrenoceptor and imidazoline receptor. Biomed Pharmacother. 2017;90:914–920.

18. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine clonidine analgesia for intractable cancer pain. Pain. 1995;61(3):391–399.

19. Guneli E, Karabay Y, Avanosoglu NU, Apaydin S, Uyar M, Uyar M. Analysis of the antinoceptive effect of systemic administration of tramadol and dexmedetomidine combination on rat models of acute and neuropathic pain. Pharmaco Biochem Behav. 2007;88(1):9–17.

20. Kimura M, Saito S, Ohata H. Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylcholine in the spinal cord. Neurosci Lett. 2012;529(1):70–74.

21. Liu L, Ji F, Liang J, He H, Fu Y, Cao M. Inhibition by dexmedetomidine of the activation of spinal dorsal horn glia and the intracellular ERK signaling pathway induced by nerve injury. Brain Res. 2012;1427:1–9.

22. Zhou TT, Wu JR, Chen ZY, Liu ZX, Miao B. Effects of dexmedetomidine on P2X4Rs, p38-MAPK and BDNF in spinal microglia in rats with spared nerve injury. Brain Res. 2014;1588:21–30.

23. Farghaly HS, Abd-Ellatif RB, Moftah MZ, Mostafa MG, Khedr EM, Koth HJ. The effects of dexmedetomidine alone and in combination with tramadol or amitriptyline in a neuropathic pain model. Pain Physician. 2014;17(2):187–195.

24. Zheng Y, Cui S, Liu Y, et al. Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-D-aspartate receptor 2B subunit. Brain Res Bull. 2012;87(4–5):427–432.

25. Villarreal CF, Funez MI, Figueiredo F, Cunha FQ, Parada CA, Ferreira SH. Acute and persistent nociceptive paw sensitisation in mice: the involvement of distinct signalling pathways. Life Sci. 2009;85(23–26):822–829.

26. Flatters SJ. Characterization of a model of persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR). Pain. 2008;135(1–2):119–130.

27. Xu JJ, Walla BC, Diaz MF, Fuller GN, Gutstein HB. Intermittent lumbar puncture in rats: a novel method for the experimental study of opioid tolerance. Anesth Analg. 2006;103(3):714–720.

28. Blaeser P, Guilemin I, Schindler J, et al. Oligomerization of KCC2 correlates with development of inhibitory neurotransmission. J Neurosci. 2006;26(41):10407–10419.

29. Buvanendran A, Kroin JS, Korns JM, Nagalla SN, Tuman KJ. Characterization of a new animal model for evaluation of persistent postthoracotomy pain. Anesth Analg. 2004;99(5):1453–1460. table of contents.

30. Ford A, Castonguay A, Cottet M, et al. Engagement of the GABA-A complex to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. J Neurosci. 2015;35(15):6057–6067.

31. Modol L, Cobianchi S, Navarro X. Prevention of NKCC1 phosphorylation avoids downregulation of KCC2 in central sensory pathways and reduces neuropathic pain after peripheral nerve injury. Pain. 2014;155(8):1577–1590.

32. Zhang C, Chen RX, Zhang Y, et al. Erratum: reduced GABAergic transmission in the ventrobasal thalamus contributes to thermal hyperalgesia in chronic inflammatory pain. Sci Rep. 2017;7:46788.

33. Coull JA, Boudreau D, Bachand K, et al. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 2003;424(6951):938–942.

34. Salarye H, Wake H, Moehhouse AJ, Nabekura J. Clustering of neuronal K+-Cl- cotransporters in lipid rafts by tyrosine phosphorylation. J Biol Chem. 2009;284(41):27980–27988.

35. Zhang W, Liu LY, Xu TL. Reduced potassium-chloride co-transporter expression in spinal cord dorsal horn neurons contributes to inflammatory pain hypersensitivity in rats. Neuroscience. 2008;152(2):502–510.

36. Meledjemian OK, Tillu DV, Asiedu MN, et al. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain. 2013;9:12.

37. Zhang HX, Zhang XQ, Xue QS, et al. The BDNF/TrkB signaling pathway is involved in heat hyperalgesia mediated by Cdk5 in rats. PLoS One. 2014;9(1):e85536.

38. Rivera C, Li H, Thomas-Crussell J, et al. BDNF-induced TrkB activation down-regulates the K+-Cl- cotransporter KCC2 and impairs neuronal Cl- extrusion. J Cell Biol. 2002;156(5):747–752.

39. Baehrke H, Yaksh TL. Pharmacologic evidence for different alpha-2 adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81(2):208–215.

40. Hayashida K, Eisenach JC. Spinal alpha2-adrenoceptor-mediated analgesia in neuropathic pain reflects brain-derived nerve growth factor and changes in spinal cholinergic neuronal function. Anesthesiology. 2010;113(2):406–412.

41. Sonohata M, Furue H, Katakuchi T, et al. Actions of noradrenaline on substantia gelatiosa neurons in the rat spinal cord revealed by in vivo patch recording. J Physiol. 2004;555(2):515–526.

42. Coull JA, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438(7070):1017–1021.